Since the beginning of the pandemic, little has been met with more anticipation (or hesitancy) than the promise of a COVID-19 vaccine. However, by mid-November 2020, less than a year after SARS-CoV-2 gained global recognition as a public health threat, this “promise” has moved from speculation to possibility, and the news has everyone talking.
A study to test the efficacy of a unique cannabis terpene formulation for the treatment of viral infections, including COVID-19, has shown early promising results.
New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19.
